Vertex and Entrada ink four-year partnership targeting muscle disorder
Andrey Prokhorov


Entrada Therapeutics (NASDAQ:TRDA) added ~13% pre-market Thursday after the biotech announced a four-year global research collaboration with Vertex Pharmaceuticals (NASDAQ:VRTX) targeting muscular disorder myotonic dystrophy type 1 (DM1).
Per the terms, Vertex (VRTX) will take over the global development, manufacturing, and commercialization of Entradaâs (TRDA) DM1 program ENTR-701, which is currently in late-stage pre-clinical studies.

Entrada (TRDA) will receive $224M in return as an upfront payment and $26M as an equity investment from Vertex (VRTX).
Additionally, the company will receive milestone-based payments worth up to $485M and tiered royalties on net sales from any products resulting from the deal, which also covers Entradaâs (TRDA) other DM1-related programs.
The partnership ârepresents an important step for Entrada as we work to make intracellular therapeutics a reality through our novel EEV approach,â Entrada (TRDA) Chief Executive Dipal Doshi said, referring to the companyâs focus on Endosomal Escape Vehicle (EEV) drugs.

Read: Seeking Alpha contributor Avisol Capital Partners explained the EEV technology as Entrada (TRDA) prepared for its IPO in 2021.